LuciAfa (Afatinib) 40mg Tablets | Lucius Laos Generic | GLT

Generic Information: LuciAfa (Afatinib) — Lucius, Laos

LuciAfa is a generic afatinib manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd., a specialist producer of oncology generics based in Laos. Supplied as 40 mg film-coated tablets in a 30-tablet pack, LuciAfa offers an accessible second-generation EGFR inhibitor for patients with EGFR-mutant non-small cell lung cancer. Lucius has built a reputation for producing affordable, quality-focused cancer medicines, and LuciAfa carries the same 40 mg strength and once-daily schedule as the originator afatinib.

What Is LuciAfa (Afatinib) Used For?

LuciAfa is used to treat non-small cell lung cancer driven by activating EGFR mutations, including exon 19 deletions, the L858R substitution, and uncommon mutations such as G719X, L861Q and S768I. It is a first-line option for EGFR-mutant NSCLC and is also used in metastatic squamous NSCLC after progression on platinum-based chemotherapy, matching the approved uses of afatinib.

How Does LuciAfa (Afatinib) Work?

LuciAfa contains afatinib, an irreversible pan-ErbB tyrosine kinase inhibitor. Its covalent binding to EGFR, HER2 and ErbB4 permanently blocks the kinase activity that EGFR-mutant cancer cells require for growth and survival. This irreversible mechanism delivers durable disease control and extends to uncommon EGFR mutations that reversible inhibitors struggle to address.

Indications

LuciAfa is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer with non-resistant EGFR mutations, and for metastatic squamous NSCLC progressing on or after platinum-based chemotherapy. EGFR mutation testing is required before treatment begins.

Dosage

The recommended dose is 40 mg once daily, taken on an empty stomach — at least one hour before or two hours after food. The 30-tablet pack is approximately one month of therapy at the standard dose. A 30 mg dose may be used for patients with severe renal impairment or to manage side effects, under medical supervision.

Side Effects

LuciAfa shares afatinib's side-effect profile: diarrhea, acneiform rash, stomatitis, paronychia, dry skin and reduced appetite are the most common. Serious reactions, including interstitial lung disease, liver toxicity and severe skin disorders, are uncommon but need prompt medical attention. Early management of diarrhea and skin symptoms supports treatment adherence.

Storage

Store LuciAfa in a cool, dry place away from direct sunlight, in its original packaging. Keep out of reach of children and swallow the tablets whole with water.

Why Choose the GLT?

LuciAfa through GLT brings the Lucius afatinib generic to patients and institutions at a price that makes long-term EGFR-targeted therapy affordable, backed by a Hong Kong-licensed supply channel. We source genuine stock, verify batch details, and provide the documentation needed for confident cross-border procurement. For those seeking a dependable, cost-conscious afatinib option, LuciAfa is a compelling choice.

How to Order LuciAfa (Afatinib)

Contact us on WhatsApp at +86 15234153837 or by email at [email protected] to order. Provide your quantity and destination, and we will confirm stock, pricing and delivery arrangements.

FAQ

Who makes LuciAfa? LuciAfa is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd., a generic oncology producer based in Laos.

Is LuciAfa the same as afatinib? Yes, LuciAfa is a generic of afatinib containing 40 mg of the same active ingredient, for the same EGFR-mutant NSCLC indications.

How long does a 30-tablet pack last? At 40 mg once daily, one pack provides 30 days — approximately one month of treatment.

Do I need a prescription? Yes, afatinib is a prescription oncology medicine and should be used under medical supervision.